Vivos Therapeutics, Inc.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- R. Kirk Huntsman
- Full Time Employees
- 268
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 7921 Southpark Plaza Littleton CO United States of America 80120
- IPO Date
- Dec 11, 2020
- CIK
- 0001716166
- Website
- vivos.com
- Similar Companies
- Business
- Vivos Therapeutics, Inc. (VVOS) operates as a medical technology company that develops and commercializes noninvasive, non-surgical treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA) across all severity levels in adults, moderate-to-severe OSA in children ages 6 to 17, snoring, and related sleep-disordered breathing conditions; its core offerings include the Vivos Method featuring Complete Airway Repositioning and/or Expansion (CARE) oral appliances—the only FDA 510(k)-cleared devices for severe OSA in adults and moderate-to-severe OSA in children—Vivos oral appliances and therapies outside the CARE system, Vivos AireO2, VivoScore screening and home sleep testing program for adults and children, Adjunctive Treatment, Treatment Navigator, Vivos Billing Intelligence Service (BIS), Vivos Airway Intelligence Service, and associated sleep testing centers with medical sleep practices. The company markets and sells these appliances, treatments, and services primarily to licensed professionals such as general dentists and medical providers in the United States and Canada, targeting patients seeking alternatives to CPAP machines and surgery through multidisciplinary protocols that address anatomical airway deficiencies with average treatment durations of about 12 months. Founded in 2016 and headquartered at 7921 Southpark Plaza, Suite 210 in Littleton, Colorado, Vivos Therapeutics focuses on the healthcare sector's medical devices industry with approximately 109 employees. Recent strategic developments include a June 2024 revenue-sharing alliance with Rebis Health to integrate Vivos-trained dental providers into sleep centers, now expanded to multiple Denver-area locations with nationwide scaling plans; the June 2025 acquisition of The Sleep Center of Nevada (SCN), its largest sleep center network serving over 200,000 OSA patients since 2019, which generated $500,000 in incremental sleep testing revenue within 20 days post-close and supports deployment of Sleep Optimizer (SO) teams for enhanced capacity and profitability; an $11.5 million net capital raise via debt and equity including from Seneca Partners to fund the SCN deal and expansions such as new Michigan collaborations; new executive appointments in July 2025 including Michael Bruhn for operations and Dr. Terry Jones to drive acquisition integrations; and ongoing exploration of further sleep center alliances or acquisitions among over 2,500 U.S. AASM-certified facilities to accelerate revenue growth, reduce cash burn, and achieve cash flow breakeven by Q4 2025.
Vivos' Vida® Appliance Shows Statistically Significant Improvement in Insomnia Severity in 100% of Study Participants
Vivos Therapeutics and Streeterville Extend Timeframe of Strategic Financing Agreement and Reaffirm Commitment to Convert Debt Into Common Stock and Perpetual Preferred Equity
Vivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering
Vivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients
Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026
Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing
Vivos Therapeutics, Inc. (VVOS) Q1 2026 Earnings Call Transcript
Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Update
Analysts see 200%+ upside in these 3 high-risk stocks: here's why?
Vivos Therapeutics Q4 Earnings Call Highlights
Vivos Therapeutics, Inc. (VVOS) Q4 2025 Earnings Call Transcript
Vivos Therapeutics Reports Full Year 2025 Financial Results
Vivos Therapeutics Schedules Release of Full Year 2025 Financial Results and Conference Call
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Short Interest Update
Vivos Therapeutics Completes Private Placement with Existing Private Equity Investor, New Seneca Partners
Vivos Therapeutics (NASDAQ:VVOS) Major Shareholder Michael Skaff Purchases 1,353,625 Shares
Vivos Therapeutics Reports that Supported Professional Practices Have Achieved 'In-Network' Status Across Multiple Commercial Health Insurers and Medicare in Key Nevada Market
Vivos Therapeutics (NASDAQ:VVOS) Trading 1.5% Higher – Should You Buy?
Recent Study Confirms Fundamental Correlation Between Severity of Obstructive Sleep Apnea and Oral Anatomy
Vivos Therapeutics and SoundHealth Announce Collaboration to Expand Access to SoundHealth's Groundbreaking FDA-Cleared Allergy and Sleep Technologies